RBC Capital Maintains Outperform on IGM Biosciences, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains an Outperform rating on IGM Biosciences but lowers the price target from $20 to $17.
October 01, 2024 | 2:25 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital has maintained its Outperform rating on IGM Biosciences but has lowered the price target from $20 to $17, indicating a more cautious outlook.
The lowering of the price target suggests a more cautious outlook on the stock's potential, which could lead to a short-term negative impact on the stock price. However, the maintained Outperform rating indicates continued confidence in the company's long-term prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100